|
10 Jan 2011 |
Excaliard Announces Positive Results From Three Phase 2 Clinical Trials for EXC 001, Showing Significant Improvement in Both Hypertrophic and Fine Line Scarring
|
|
10 Jan 2011 |
Sangamo BioSciences Announces Completion of Enrollment of Phase 2b Clinical Trial in Diabetic Neuropathy
|
|
10 Jan 2011 |
Interim Results From Mesoblast's Phase 2 Heart Failure Trial Shows 'Off-The-Shelf' Proprietary Adult Stem Cell Product Revascor Reduces Cardiac Events, Mortality, and Hospitalization
|
|
10 Jan 2011 |
Bioheart Reports Positive Results for Adipose Derived Stem Cells in Critical Limb Ischemia
|
|
07 Jan 2011 |
ZIOPHARM Oncology and Intrexon Announce Worldwide Partnership for Synthetic Biology DNA-based Oncology Therapeutics
|
|
06 Jan 2011 |
Cell Medica Signs an Exclusive License Agreement and Strengthens Collaboration With the Center for Cell and Gene Therapy, Baylor College of Medicine
|
|
05 Jan 2011 |
Aldagen Announces FDA Clearance of IND to Begin Phase 2 Study in Ischemic Stroke With Regenerative Cell Therapy
|
|
05 Jan 2011 |
AVI BioPharma and Leading Researchers at Karolinska Institutet Form Collaboration to Identify RNA-Based Therapeutic Candidates for Treatment of Extensively Drug-Resistant Tuberculosis (XDR-TB)
|
|
04 Jan 2011 |
Kiadis Pharma Signs License Agreement with Hospira to Commercialize ATIR in Europe and Asia
|
